{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:09:52Z","timestamp":1787062192925,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1038\/sj.leu.2404539","type":"journal-article","created":{"date-parts":[[2007,2,2]],"date-time":"2007-02-02T22:46:11Z","timestamp":1170456371000},"page":"739-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines"],"prefix":"10.1038","volume":"21","author":[{"given":"B C","family":"Medeiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H J","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R O","family":"Lockerbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S G","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,1]]},"reference":[{"key":"BF2404539_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1053\/shem.2002.35984","volume":"39","author":"JE Cortes","year":"2003","unstructured":"Cortes JE, Kurzrock R, Kantarjian HM . Future clinical implications for farnesyl transferase inhibitors in hematologic malignancies. Semin Hematol 2003; 39: 26\u201330.","journal-title":"Semin Hematol"},{"key":"BF2404539_CR2","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1200\/JCO.1999.17.11.3569","volume":"17","author":"W Hiddemann","year":"1999","unstructured":"Hiddemann W, Kern W, Schoch, Fonatsch C, Heinecke A, Wormann B et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569\u20133576.","journal-title":"J Clin Oncol"},{"key":"BF2404539_CR3","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood.V100.4.1224.h81602001224_1224_1232","volume":"100","author":"MR Baer","year":"2002","unstructured":"Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224\u20131232.","journal-title":"Blood"},{"key":"BF2404539_CR4","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","volume":"189","author":"C Leith","year":"1997","unstructured":"Leith C, Kopecky KJ, Godwin J . Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A southwest oncology group study. Blood 1997; 189: 3323\u20133329.","journal-title":"Blood"},{"key":"BF2404539_CR5","first-page":"1491","volume":"9","author":"N Dastugue","year":"1995","unstructured":"Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F et al. Prognostic significance of kayrotype in de novo adult acute myeloid leukemia. Leukemia 1995; 9: 1491\u20131498.","journal-title":"Leukemia"},{"key":"BF2404539_CR6","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood.V94.9.2971","volume":"94","author":"A Rebollo","year":"1999","unstructured":"Rebollo A, Martrinez-A C . RAS proteins: recent advances and new functions. Blood 1999; 94: 2971\u20132980.","journal-title":"Blood"},{"key":"BF2404539_CR7","first-page":"F51","volume":"1333","author":"AD Cox","year":"1997","unstructured":"Cox AD, Der CJ . Farnesyltransferase inhibitors and cancer treatment: targeting simply RAS? Biochem Biophys Acta 1997; 1333: F51\u2013F71.","journal-title":"Biochem Biophys Acta"},{"key":"BF2404539_CR8","first-page":"5302","volume":"55","author":"L Sepp-Lorenzino","year":"1995","unstructured":"Sepp-Lorenzino L, Ma Z, Rands E . A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302\u20135309.","journal-title":"Cancer Res"},{"key":"BF2404539_CR9","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/sj.onc.1202175","volume":"17","author":"PF Lebowitz","year":"1998","unstructured":"Lebowitz PF, Prendergast GC . Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 1998; 17: 1439\u20131445.","journal-title":"Oncogene"},{"key":"BF2404539_CR10","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S1470-2045(00)00191-1","volume":"2","author":"SRD Johnston","year":"2001","unstructured":"Johnston SRD . Farnesyl transferase inhibitors: a novel targeted therapy for cancer. Lancet 2001; 2: 18\u201326.","journal-title":"Lancet"},{"key":"BF2404539_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1128\/MCB.20.1.139-148.2000","volume":"20","author":"K Jiang","year":"2000","unstructured":"Jiang K, Coppola D, Crespo NC . The phosphoinositide 3-OH kinase\/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cel Biol 2000; 20:139\u2013148.","journal-title":"Mol Cel Biol"},{"key":"BF2404539_CR12","first-page":"7525","volume":"61","author":"E Wang","year":"2001","unstructured":"Wang E, Casciano CN, Clement RP, Johnson WW . The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of the MDR1 product p-glycoprotein. Cancer Res 2001; 61: 7525\u20137529.","journal-title":"Cancer Res"},{"key":"BF2404539_CR13","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0090-9556(24)15095-7","volume":"28","author":"E-J Wang","year":"2000","unstructured":"Wang E-J, Casciano CN, Clement RP, Johnson WW . In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein. Drug Metab Disp 2000; 28: 522\u2013528.","journal-title":"Drug Metab Disp"},{"key":"BF2404539_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27\u201355.","journal-title":"Adv Enzyme Regul"},{"key":"BF2404539_CR15","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1182\/blood.V87.12.4959.bloodjournal87124959","volume":"87","author":"J Estaquier","year":"1996","unstructured":"Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC . Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood 1996; 87: 4959\u20134966.","journal-title":"Blood"},{"key":"BF2404539_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-3-642-58259-2_2","volume-title":"Stress Proteins","author":"L Neckers","year":"1999","unstructured":"Neckers L, Mimnaugh E, Schulte TW . The Hsp90 chaperone family. In: Latchman DS (eds.), Stress Proteins. Springer-Verlag, New York, 1999, 9\u201342."},{"key":"BF2404539_CR17","first-page":"3894","volume":"7","author":"CD Britten","year":"2001","unstructured":"Britten CD, Rowinsky EK, Soignet S . A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin Cancer Res 2001; 7: 3894\u20133903.","journal-title":"Clin Cancer Res"},{"key":"BF2404539_CR18","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","volume":"97","author":"JE Karp","year":"2001","unstructured":"Karp JE, Lancet JE, Kaufmann SH . . Blood 2001; 97: 3361\u20133369.","journal-title":"Blood"},{"key":"BF2404539_CR19","first-page":"2318","volume":"6","author":"AA Adjei","year":"2000","unstructured":"Adjei AA, Davis JN, Ehrlichman C, Svingen PA, Kaufman SH . Comparison of potential markers of farnesyltransferase inhibition. Clin Cancer Res 2000; 6: 2318\u20132325.","journal-title":"Clin Cancer Res"},{"key":"BF2404539_CR20","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","volume":"17","author":"EK Rowinsky","year":"1999","unstructured":"Rowinsky EK, Windle JJ, Von Hoff DD . Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631\u20133652.","journal-title":"J Clin Oncol"},{"key":"BF2404539_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1023\/A:1006380320290","volume":"17","author":"DW End","year":"1999","unstructured":"End DW . Farnesyl protein transferase inhibitors and other therapies targeting RAS signal transduction pathway. Invest New Drugs 1999; 17: 241\u2013258.","journal-title":"Invest New Drugs"},{"key":"BF2404539_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/0005-2736(95)00224-3","volume":"1278","author":"RI Ghauharali","year":"1996","unstructured":"Ghauharali RI, Westerhoff HV, Dekker H, Lankelma J . Saturable P-glycoprotein kinetics assayed by fluorescence studies of drug efflux from suspended human KB8-5 cells. Biochem Biophys Acta 1996; 1278: 213\u2013222.","journal-title":"Biochem Biophys Acta"},{"key":"BF2404539_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00001813-200103000-00003","volume":"12","author":"CJ Punt","year":"2001","unstructured":"Punt CJ, van Maanen L, Bol CJ, Seifert WF, Wagener DJ . Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 2001; 12: 193\u2013197.","journal-title":"Anticancer Drugs"},{"key":"BF2404539_CR24","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1046\/j.1432-1327.1998.2550383.x","volume":"255","author":"G Wang","year":"1998","unstructured":"Wang G, Pincheira R, Zhang JT . Dissection of drug-binding-induced conformation changes in P-glycoprotein. Eur J Biochem 1998; 255: 388\u2013390.","journal-title":"Eur J Biochem"},{"key":"BF2404539_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1365-2710.2003.00487.x","volume":"28","author":"RB Wang","year":"2003","unstructured":"Wang RB, Kuo CL, Lien LL, Lien EJ . Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003; 28: 203\u2013228.","journal-title":"J Clin Pharm Ther"},{"key":"BF2404539_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/AAC.46.1.160-165.2002","volume":"46","author":"EJ Wang","year":"2000","unstructured":"Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW . Interaction of common azole antifungals with P-glycoprotein. Antimicrob Agents Chemother 2000; 46: 160\u2013165.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF2404539_CR27","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1038\/sj.leu.2403063","volume":"17","author":"JL Liesveld","year":"2003","unstructured":"Liesveld JL, Lancet JE, Rosell KE . Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia 2003; 17: 1806\u20131812.","journal-title":"Leukemia"},{"key":"BF2404539_CR28","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/00001813-200209000-00016","volume":"13","author":"F Caponigro","year":"2002","unstructured":"Caponigro F . Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Anticancer Drugs 2002; 13: 891\u2013897.","journal-title":"Anticancer Drugs"},{"key":"BF2404539_CR29","first-page":"511","volume":"2","author":"E Kokenberg","year":"1998","unstructured":"Kokenberg E, Sonneveld P, Delwel R, Sizoo W, Hagenbeek A, Lowenberg B . In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 1998; 2: 511\u2013517.","journal-title":"Leukemia"},{"key":"BF2404539_CR30","first-page":"825","volume":"7","author":"JP Marie","year":"1993","unstructured":"Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R . Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia 1993; 7: 825\u2013831.","journal-title":"Leukemia"},{"key":"BF2404539_CR31","first-page":"1007","volume":"5","author":"DL Persons","year":"1999","unstructured":"Persons DL, Yazlovitskaya EM, Cui W, Pelling JC . Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999; 5: 1007\u20131014.","journal-title":"Clin Cancer Res"},{"key":"BF2404539_CR32","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1038\/sj.onc.1207426","volume":"23","author":"PY Yeh","year":"2004","unstructured":"Yeh PY, Chuang SE, Yeh KH, Song YC, Chang LL, Cheng AL . Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 2004; 23: 3580\u20133588.","journal-title":"Oncogene"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404539","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T04:09:32Z","timestamp":1736741372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["BF2404539"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404539","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,1]]},"assertion":[{"value":"6 May 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}